Myelin Basic Protein in Oligodendrocyte-Derived Extracellular Vesicles as a Diagnostic and Prognostic Biomarker in Multiple Sclerosis: A Pilot Study
International Journal of Molecular Sciences · 03.01.2023 · 24 (1) · 894
DOI: 10.3390/ijms24010894 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 03.01.2023. Verfasst von Cristina Agliardi und 8 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy. Hauptthemen laut MEDLINE: Extracellular Vesicles, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting, Myelin Basic Protein. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Governo Italiano: Ricerca Corrente, Fondazione Alessandro e Vincenzo Negroni Prati Morosini, Fondazione Romeo ed Enrica Invernizzi.
Abstract (Originalsprache)
Approximately 15% of multiple sclerosis (MS) patients develop a progressive form of disease from onset; this condition (primary progressive-PP) MS is difficult to diagnose and treat, and is associated with a poor prognosis. Extracellular vesicles (EVs) of brain origin isolated from blood and their protein cargoes could function as a biomarker of pathological conditions. We verified whether MBP and MOG content in oligodendrocytes-derived EVs (ODEVs) could be biomarkers of MS and could help in the differential diagnosis of clinical MS phenotypes. A total of 136 individuals (7 clinically isolated syndrome (CIS), 18 PPMS, 49 relapsing remitting (RRMS)) and 70 matched healthy controls (HC) were enrolled. ODEVs were enriched from serum by immune-capture with anti-MOG antibody; MBP and MOG protein cargoes were measured by ELISA. MBP concentration in ODEVs was significantly increased in CIS (p < 0.001), RRMS (p < 0.001) and PPMS (p < 0.001) compared to HC and was correlated with disease severity measured by EDSS and MSSS. Notably, MBP concentration in ODEVs was also significantly augmented in PPMS compared to RRMS (p = 0.004) and CIS (p = 0.03). Logistic regression and ROC analyses confirmed these results. A minimally invasive blood test measuring the concentration of MBP in ODEVs is a promising tool that could facilitate MS diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCCS Fondazione Don Carlo Gnocchi, 20147 Milan, Italy.
- Pathophysiology and Transplantation Department, University of Milan, 20122 Milan, Italy.
ORCID-Profile: Cristina Agliardi, Franca Rosa Guerini, Elisabetta Bolognesi, Silvia Picciolini
Förderung
- Governo Italiano: Ricerca Corrente
- Fondazione Alessandro e Vincenzo Negroni Prati Morosini
- Fondazione Romeo ed Enrica Invernizzi
- Italian Ministry of Health
Zitieren
APA
Agliardi, C., Guerini, F. R., Zanzottera, M., Bolognesi, E., Picciolini, S., Caputo, D., Rovaris, M., Pasanisi, M. B., & Clerici, M. (2023). Myelin Basic Protein in Oligodendrocyte-Derived Extracellular Vesicles as a Diagnostic and Prognostic Biomarker in Multiple Sclerosis: A Pilot Study. International Journal of Molecular Sciences, 24(1), 894. https://doi.org/10.3390/ijms24010894
Vancouver
Agliardi C, Guerini FR, Zanzottera M, Bolognesi E, Picciolini S, Caputo D, et al. Myelin Basic Protein in Oligodendrocyte-Derived Extracellular Vesicles as a Diagnostic and Prognostic Biomarker in Multiple Sclerosis: A Pilot Study. International Journal of Molecular Sciences. 2023;24(1):894. doi:10.3390/ijms24010894
BibTeX
@article{Agliardi2023,
author = {Agliardi, Cristina and Guerini, Franca Rosa and Zanzottera, Milena and Bolognesi, Elisabetta and Picciolini, Silvia and Caputo, Domenico and Rovaris, Marco and Pasanisi, Maria Barbara and Clerici, Mario},
title = {Myelin Basic Protein in Oligodendrocyte-Derived Extracellular Vesicles as a Diagnostic and Prognostic Biomarker in Multiple Sclerosis: A Pilot Study},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {1},
pages = {894},
doi = {10.3390/ijms24010894}
}
EUVIMED